What is Kyprolis?
Kyprolis®, also known as carfilzomib, is a next generation proteasome inhibitor in the same drug class as Velcade® (bortezomib, Takeda Oncology). Kyprolis is made by Onyx Pharmaceuticals, a subsidiary of Amgen.
The MMRF and its affiliate organization, the Multiple Myeloma Research Consortium (MMRC), played an integral role in the development of Kyprolis. The MMRC provided clinical trial support and resources, including driving patient enrollment to the study which lead to the approval of Kyprolis for treating multiple myeloma.